Navigation Links
Texas A&M research produces tools to study stallions' subfertility
Date:8/26/2010

COLLEGE STATION, Aug. 26, 2010 Subfertility of breeding stallions meaning the horses are less able to sire foals is a well-recognized problem that has caused multi-million-dollar losses in the equine industry, experts say. Texas A&M researchers believe they are making progress in solving the problem by using an approach that might provide tools and resources necessary to study subfertility without causing stallions the angst of providing testicular samples for testing.

They have developed protocols to isolate RNAwhich carries the information of genes in DNA from stallion sperm and testis biopsies so that genetic factors associated with this condition can be identified.

Researchers from the Departments of Veterinary Integrative Biosciences (VIBS) and Large Animal Clinical Sciences had their results published online in the journal Theriogenology. The leading author of the published research is Dr. Terje Raudsepp, an assistant professor from VIBS, and the first author is Dr. Pranab J. Das, a postdoctoral research assistant from the same department.

The RNA isolation technique from stallion sperm is believed to lead to the discovery of fertility biomarkers that could improve breeding procedures and raise thoroughbred race horses.

"Because of the structure of horse breeding, where one stallion covers many mares, the economy of the breeding industry is more sensitive to the fertility of the stallion than the mare," Das says.

"During past decades, several organized studies have been conducted to understand the role of various environmental, behavioral and physiological factors affecting fertility in horses," adds Raudsepp, the project leader. "However, very little is known about the genetic factors associated with stallion fertility, and genetic factors of male fertility involve the interplay of hundreds of genes."

Obtaining testis tissue by surgery could harm the horse, so the research team studied an alternative RNA isolation from sper
'/>"/>

Contact: Keith Randall
keith-randall@tamu.edu
979-845-4644
Texas A&M University
Source:Eurekalert

Page: 1 2

Related biology news :

1. A river flipped: Humans trump nature on Texas river
2. Texas petrochemical emissions down, but still underestimated, says study
3. Texas A&M spring graduate contributes to mental retardation research published in Nature
4. Chances of hurricane hitting Texas discussed at UH conference
5. Texas A&M veterinary researchers achieve cloning first
6. Texas Childrens Hospital vaccine experts present 4 studies
7. New bony-skulled dinosaur species discovered in Texas
8. Texas Childrens Cancer Center first in Texas to magnetically lengthen nine-year-olds leg as she grows
9. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
10. Biogas technology with potential to save thousands of lives to be featured at Texas event
11. Quickly and easily integrate fingerprint biometric features into portable applications with Texas Instruments comprehensive, low cost fingerprint development kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... drug-delivery devices and fire extinguishers to improve spray technologies, ... of Swedish Biomimetics 3000 Ltd, in Aprils Physics World. ... Asia, is remarkable in that it can fire a ... predators such as birds and frogs. While the ...
... of changes to the microbes that live in them just ... by global warming, according to scientists speaking today (Wednesday 2 ... being held this week at the Edinburgh International Conference Centre. ... knife edge. Corals in coral reefs, which are made up ...
... SPRING HARBOR, N.Y. (Tuesday, April 1, 2008) ... processes in the mouse used to be a monumental ... search, making it effective for even the smallest laboratories. ... Protocols ( www.cshprotocols.org/TOCs/toc4_08.dtl ) highlights a method for ...
Cached Biology News:The bombardier beetle, power venom and spray technologies 2Coral reefs and climate change: Microbes could be the key to coral death 2Coral reefs and climate change: Microbes could be the key to coral death 3Cold Spring Harbor Protocols features methods to screen genomes and analyze evolution 2
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas ... Bi-Gel, a nighttime-specific product that targets fat cells for extreme contouring action. During ... enter fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks ...
(Date:7/28/2015)... July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines to ... Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a recently-formed ... ( c. £76.5m), gross, from blue chip institutional investors ...
(Date:7/28/2015)... , July 28, 2015 Seahorse Bioscience, ... metabolism, is the provider of XF Technology which ... disease research areas. As the links between mitochondrial ... cell metabolism is escalating rapidly.   ... the Nature Publishing Group (NPG) featuring XF Technology, ...
(Date:7/28/2015)... , July 28, 2015 Deerfield Management Company, ... Innovations Fund, L.P., which will invest in groundbreaking advancements ... genetic diseases, cancer, and orphan diseases. The venture capital ... how therapeutics are developed and improve the way healthcare ... of the largest healthcare-focused venture funds in the sector, ...
Breaking Biology Technology:Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3
... Insmed Incorporated (Nasdaq CM: INSM), a ... J.D. has been appointed to the newly created position ... effective as of July 18, 2011.  Ms. Drucker, who ... Executive Officer of Insmed, will provide strategic legal and ...
... , 90% , Reduction ... Compared With Normal Disease Progression SEEK, a ... completed a Phase Ib/II,clinical trial of its HIV-v vaccine ... in HIV-infected,people compared with the placebo group, after just a single ...
... Champions Oncology, Inc., formerly Champions Biotechnology, Inc., (OTC: CSBR): ... 2011 Revenue growth of 41% to $6.9 million ... net loss of $0.7 million* Net loss of ... Cash of $10.5 million at year end ...
Cached Biology Technology:Andrea Drucker Joins Insmed as General Counsel 2Andrea Drucker Joins Insmed as General Counsel 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 2SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 4SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 5SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 6Champions Oncology Reports Full Year 2011 Financial Results 2Champions Oncology Reports Full Year 2011 Financial Results 3Champions Oncology Reports Full Year 2011 Financial Results 4Champions Oncology Reports Full Year 2011 Financial Results 5Champions Oncology Reports Full Year 2011 Financial Results 6